Meribank Biotech Co., Ltd (TPEX:4724)

Revenue by Product

Financials in millions TWD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Stem Cell	228.03M
Stem Cell Growth	9.93%
Management Consulting	88.24M
Other	50.16M
Other Growth	86.43%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Taiwan	366.43M
Taiwan Growth	56.37%